Profound Medical Corp., a commercial-stage medical device company developing AI-powered, MRI-guided therapeutic systems, is expected to reach profitability by 2028, according to five industry analysts. The company, with a CA$341 million market capitalisation, posted a US$43 million loss for its most recent financial year ending 31 December 2025. Analysts forecast Profound Medical will post its final loss in 2027 before turning a profit of US$9.4 million in 2028, approximately two years from now. Achieving this requires an average annual growth rate of 53%. The company has managed capital prudently, with debt comprising just 6.8% of equity, predominantly funding operations through equity capital. This low debt obligation reduces investment risk for the loss-making company.

Profound Medical showcased clinical data and software upgrades for its TULSA prostate treatment system at a recent conference. CAPTAIN-era data showed TULSA patients returned to work faster than robotic prostatectomy patients (10 versus 19 days) with zero hospitalisations versus over 6%. The company is scaling AI tools including Thermal Boost Contouring Assistant and partnering with Siemens and Cook on compact interventional MRI systems. Revenue grew from approximately CAD 10 million in 2024 to CAD 16 million in 2025, with management projecting high double-digit growth and potential profitability at around 200 sites. TULSA uses MRI-guided ultrasound ablation without incisions, positioning itself between robotic prostatectomy and focal therapy. The company estimates a 600,000-patient addressable market with roughly $500,000 capital costs plus $5,500 per-patient disposables.

Profound Medical reported Q4 2025 revenue of $6.0 million, a 43% year-on-year increase, comprising $2.3 million in recurring revenue and $3.7 million from capital equipment sales. Gross margin declined to 67% from 71% the previous year, whilst the company posted a net loss of CAD 8.2 million with CAD 59.7 million cash on hand. The company announced completion of recruitment and treatments for its CAPTAIN trial, comparing its technology to robotic radical prostatectomy for localised prostate cancer. Primary safety and quality-of-life endpoints will be presented at the European Association of Urology meeting on 13 March. Profound ended 2025 with 78 TULSA-PRO sites and a 110-system pipeline, targeting profitability around $80-85 million revenue.